Page last updated: 2024-10-22

albuterol and Obesity

albuterol has been researched along with Obesity in 26 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Achievement of asthma control as defined by the global initiative on asthma guidelines (GINA) was examined in 1242 asthmatic patients not currently using ICS, enrolled in five clinical trials comparing fluticasone propionate and the combination of fluticasone and salmeterol."7.74Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. ( Boulet, LP; Franssen, E, 2007)
"To determine whether adiposity worsens the clinical and physiological manifestations of acute asthma and limits therapeutic effectiveness of standard treatment, we contrasted signs, symptoms, medication use, arterial oxygen saturation, peak expiratory flow rate, and the bronchodilator response to standard doses of albuterol in 90 non-obese and 90 obese asthmatics as they presented for urgent care."5.15Impact of obesity on the severity and therapeutic responsiveness of acute episodes of asthma. ( Coreno, AJ; Dickey-White, H; McFadden, ER; Seitz, RE; Skowronski, ME; Villalba, KD; Yeh, KH, 2011)
"We examined the baseline change in FEV1 and FVC in response to albuterol among 931 participants with poorly controlled asthma pooled from three clinical trials conducted by the American Lung Association - Airways Clinical Research Centers."4.31Bronchodilator response does not associate with asthma control or symptom burden among patients with poorly controlled asthma. ( Dixon, AE; He, J; Henderson, R; Holbrook, JT; Irvin, CG; Kaminsky, DA; Mastronarde, J; Smith, LJ; Sugar, EA; Wise, RA, 2023)
"Seventy nonasthmatic children, 8-12 years old, without (n = 19) and with (n = 51) obesity, completed spirometry, impulse oscillometry, and airway resistance measurements through plethysmography pre/post 360 µg of inhaled albuterol."4.12Mechanical effects of obesity on central and peripheral airway resistance in nonasthmatic early pubescent children. ( Babb, TG; Bhammar, DM; Martinez-Fernandez, T; Wilhite, DP, 2022)
"Achievement of asthma control as defined by the global initiative on asthma guidelines (GINA) was examined in 1242 asthmatic patients not currently using ICS, enrolled in five clinical trials comparing fluticasone propionate and the combination of fluticasone and salmeterol."3.74Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. ( Boulet, LP; Franssen, E, 2007)
"Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment."2.80Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. ( Beasley, R; Bowles, D; Charles, T; Fingleton, J; Shirtcliffe, P; Strik, R; Travers, J; Weatherall, M; Williams, M, 2015)
"Caffeine and ephedrine was an effective combination therapy for weight loss until ephedrine was removed from the market due to safety concerns."2.80The effect of caffeine and albuterol on body composition and metabolic rate. ( Arceneaux, KP; Chu, JT; Greenway, FL; Jacob, G; Johnson, WD; Liu, AG; Primeaux, SD; Schreiber, AL; Tipton, RC; Yu, Y, 2015)
"Obesity was defined as BMI ≥95%."1.72Association of obesity with severity outcomes in hospitalized pediatric asthma exacerbations. ( Arca, M; Delgado, Y; Isbell, T; Parlar-Chun, R; Truong, G, 2022)
"Obesity is a metabolic disorder that predisposes to numerous diseases and has become a major global public health concern."1.48Obesity alters the uterine environment before pregnancy. ( Bazzano, MV; Berón de Astrada, M; Elia, EM; Martinez, N; Sarrible, GB, 2018)
"Obesity is associated with poor asthma control, increased asthma morbidity, and decreased response to inhaled corticosteroids."1.42Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma. ( Avila, PC; Bibbins-Domingo, K; Borrell, LN; Brigino-Buenaventura, E; Burchard, EG; Castellanos, E; Davis, A; Eng, C; Farber, HJ; Kumar, R; LeNoir, MA; McGarry, ME; Meade, K; Oh, SS; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Sen, S; Serebrisky, D; Thakur, N; Thyne, SM, 2015)
"One of them, obesity, has been reported to exert a harmful influence on asthma control."1.37Influence of obesity on control in asthmatic Japanese patients defined by the Japanese definition of obesity. ( Arakawa, M; Gejyo, F; Hasegawa, T; Koya, T; Narita, I; Sakagami, T; Suzuki, E; Suzuki, K; Toyabe, S; Youkou, A, 2011)
"Obesity is a social disease and amounts to a real medical problem."1.29[Obesity: a multifactorial disorder with difficult long-term treatment]. ( Cotrozzi, G; Fontana, R; Relli, P, 1994)
"After an additional 12 days of treatment, weight gain decreased significantly accompanied by no appetite suppression."1.29Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. ( Shaw, WN, 1993)
" Dose-response curves show similar sensitivity, but decreased responsiveness in the lean animal."1.28Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists. ( Bray, GA; Tsujii, S, 1992)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.85)18.7374
1990's5 (19.23)18.2507
2000's8 (30.77)29.6817
2010's9 (34.62)24.3611
2020's3 (11.54)2.80

Authors

AuthorsStudies
Wilhite, DP1
Bhammar, DM1
Martinez-Fernandez, T1
Babb, TG1
Kaminsky, DA1
He, J1
Henderson, R1
Dixon, AE1
Irvin, CG1
Mastronarde, J1
Smith, LJ1
Sugar, EA1
Wise, RA1
Holbrook, JT1
Parlar-Chun, R1
Truong, G1
Isbell, T1
Delgado, Y1
Arca, M1
Bazzano, MV1
Sarrible, GB1
Martinez, N1
Berón de Astrada, M1
Elia, EM1
Desai, AG1
Togias, A1
Schechter, C1
Fisher, B1
Parow, A1
Skloot, G1
McGarry, ME1
Castellanos, E1
Thakur, N1
Oh, SS1
Eng, C1
Davis, A1
Meade, K1
LeNoir, MA1
Avila, PC1
Farber, HJ1
Serebrisky, D1
Brigino-Buenaventura, E1
Rodriguez-Cintron, W1
Kumar, R1
Bibbins-Domingo, K1
Thyne, SM1
Sen, S1
Rodriguez-Santana, JR1
Borrell, LN1
Burchard, EG1
Fingleton, J1
Travers, J1
Williams, M1
Charles, T1
Bowles, D1
Strik, R1
Shirtcliffe, P1
Weatherall, M1
Beasley, R1
Liu, AG1
Arceneaux, KP1
Chu, JT1
Jacob, G1
Schreiber, AL1
Tipton, RC1
Yu, Y1
Johnson, WD1
Greenway, FL1
Primeaux, SD1
Teixeira, VP1
Cervilha, DA1
Cabral, LD1
Oliveira, LM1
Incerpi, EK1
Novaes, RD1
Ionta, M1
Soncini, R1
Rajendran, S1
Willoughby, SR1
Chan, WP1
Liberts, EA1
Heresztyn, T1
Saha, M1
Marber, MS1
Norman, RJ1
Horowitz, JD1
Camargo, CA1
Boulet, LP2
Sutherland, ER1
Busse, WW1
Yancey, SW1
Emmett, AH1
Ortega, HG1
Ferro, TJ1
Yeh, KH1
Skowronski, ME1
Coreno, AJ1
Seitz, RE1
Villalba, KD1
Dickey-White, H1
McFadden, ER1
Youkou, A1
Hasegawa, T1
Suzuki, K1
Koya, T1
Sakagami, T1
Toyabe, S1
Arakawa, M1
Gejyo, F1
Narita, I1
Suzuki, E1
Schiffelers, SL3
Akkermans, JA1
Saris, WH4
Blaak, EE2
Mensink, M1
Kooi, ME1
Suh, HS1
Park, YW1
Kang, JH1
Lee, SH1
Lee, HS1
Shim, KW1
Oomen, JM1
van Rossum, CT1
Hoebee, B1
van Baak, MA2
Franssen, E1
Rodrigo, GJ1
Plaza, V1
Bégin-Heick, N1
Cotrozzi, G1
Relli, P1
Fontana, R1
Shaw, WN1
Boomsma, F1
Kuhn, JM1
Courtois, H1
Brunelle, P1
Schrub, JC1
Mazza, P1
Salvadori, A1
Baudo, S1
Fanari, P1
Fontana, M1
Ruga, S1
Longhini, E1
Tsujii, S1
Bray, GA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect on Body Composition With Albuterol and Caffeine Versus Placebo in Adolescents: A Pilot Study[NCT02740660]12 participants (Actual)Interventional2016-04-30Completed
An 8-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler) in Asth[NCT03084718]Phase 2610 participants (Actual)Interventional2017-07-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Fat Mass With Caffeine/Albuterol

DXA Scan of obese adolescents (NCT02740660)
Timeframe: Baseline, Week 8

Interventionkg (Mean)
Caffeine 100mg / Albuterol 4mg0.97
Placebo-0.21

Change in Lean Mass With Caffeine/Albuterol

DXA Scan of obese adolescents (NCT02740660)
Timeframe: Baseline, Week 8

Interventionkg (Mean)
Caffeine 100mg / Albuterol 4mg1.34
Placebo0.88

Change in Weight With Caffeine/Albuterol

(NCT02740660)
Timeframe: Baseline, Week 8

Interventionkg (Mean)
Caffeine 100mg / Albuterol 4mg2.57
Placebo1.05

Number of Participants With Adverse Events

(NCT02740660)
Timeframe: Week 2, Week 4, Week 6, Week 8

InterventionParticipants (Count of Participants)
Caffeine 100mg / Albuterol 4mg5
Placebo2

12-lead ECG Parameters - Heart Rate - Change From Baseline

"12-lead electrocardiogram (12-lead ECG) parameter - heart rate (HR) was measured at baseline (Day 1) and Week 8.~Change from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;~bpm=Beats per minute;" (NCT03084718)
Timeframe: Baseline, Week 8

Interventionbpm (Mean)
Treatment A (CHF 718 pMDI 100 µg TDD)0.6
Treatment B (CHF 718 pMDI 400 µg TDD)0.2
Treatment C (CHF 718 pMDI 800 µg TDD)0.4
Treatment D (Placebo)1.2
Treatment E (QVAR^®, 320 µg TDD)-0.4

24-hr Creatinine - Change From Baseline.

"24-hr Creatinine - Change From Baseline.~For the evaluation of the 24-hr creatinine excretion, 24-hour urine sample were collected. Creatinine was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;" (NCT03084718)
Timeframe: Baseline, Week 8

Interventionumol/mol (Median)
Treatment A (CHF 718 pMDI 100 µg TDD)0.00
Treatment B (CHF 718 pMDI 400 µg TDD)0.00
Treatment C (CHF 718 pMDI 800 µg TDD)0.00
Treatment D (Placebo)0.00
Treatment E (QVAR^®, 320 µg TDD)0.00

24-hr Urine Free Cortisol - Change From Baseline

"24-hr Urinary Free Cortisol - Change From Baseline.~For the evaluation of the 24-hr Urine-Free cortisol excretion, 24-hour urine samples were collected. Urine-free cortisol was measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS).~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose;" (NCT03084718)
Timeframe: Baseline, Week 8

Interventionnmol/day (Median)
Treatment A (CHF 718 pMDI 100 µg TDD)-3.60
Treatment B (CHF 718 pMDI 400 µg TDD)-5.35
Treatment C (CHF 718 pMDI 800 µg TDD)-4.10
Treatment D (Placebo)1.40
Treatment E (QVAR^®, 320 µg TDD)-3.50

Pre-dose Morning FEV1 at Week 4 - Change From Baseline

"Change from baseline in pre-dose morning FEV1 at Week 4.~Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FEV1 were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 4

InterventionLitres (Least Squares Mean)
Treatment A (CHF 718 pMDI 100 µg TDD)0.021
Treatment B (CHF 718 pMDI 400 µg TDD)0.120
Treatment C (CHF 718 pMDI 800 µg TDD)0.073
Treatment D (Placebo)0.003
Treatment E (QVAR^®, 320 µg TDD)0.077

Pre-dose Morning FEV1 at Week 8 - Change From Baseline

"Change from baseline in pre-dose morning FEV1 (average of pre-dose FEV1 measurements) at Week 8.~Spirometry, used to measure FEV1, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FEV1 were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 8

InterventionLitres (Least Squares Mean)
Treatment A (CHF 718 pMDI 100 µg TDD)0.021
Treatment B (CHF 718 pMDI 400 µg TDD)0.090
Treatment C (CHF 718 pMDI 800 µg TDD)0.070
Treatment D (Placebo)-0.023
Treatment E (QVAR^®, 320 µg TDD)0.078

12-lead ECG Parameters - PR, QRS, QTcF - Change From Baseline.

"12-lead electrocardiogram (12-lead ECG) parameters - PR, QRS, QTcF intervals - were measured at baseline (Day 1) and Week 8.~Changes from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0); QTcF=Fridericia-corrected QT interval; msec=Millisecond;" (NCT03084718)
Timeframe: Baseline, Week 8

,,,,
Interventionmsec (Mean)
PRQRSQTcF
Treatment A (CHF 718 pMDI 100 µg TDD)-2.60.11.6
Treatment B (CHF 718 pMDI 400 µg TDD)1.5-1.30.7
Treatment C (CHF 718 pMDI 800 µg TDD)-1.90.90.7
Treatment D (Placebo)-1.3-0.54.6
Treatment E (QVAR^®, 320 µg TDD)1.0-0.31.2

12-lead ECG Parameters - Prolonged QTcF - Change From Baseline

"Number of participants with prolonged QTcF. Change from baseline.~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose; QTcF=Fridericia-corrected QT interval;" (NCT03084718)
Timeframe: Baseline, Week 8

,,,,
InterventionParticipants (Count of Participants)
QTcF > 30 msecQTcF > 60 msec
Treatment A (CHF 718 pMDI 100 µg TDD)61
Treatment B (CHF 718 pMDI 400 µg TDD)41
Treatment C (CHF 718 pMDI 800 µg TDD)40
Treatment D (Placebo)92
Treatment E (QVAR^®, 320 µg TDD)31

Asthma Control Questionnaire-7© (ACQ-7) Score at Week 4 and Week 8 - Change From Baseline

"The ACQ consists of 7 items: 6 simple self-administered questions referring to asthma control and rescue treatment usage with 1 week recall, and a 7th item consisting of the percent (%) predicted FEV1 completed by clinic staff. Scoring uses a 7-point scale: 0 = totally controlled and 6 = severely uncontrolled. The ACQ score was calculated as the average of all 7 items.~Definitions:~ACQ-7 score=Asthma Control Questionnaire-7©; Information regarding the American Thoracic Society ACQ questionnaire is also available at: https://member.thoracic.org/members/assemblies/assemblies/srn/questionaires/acq.php; Baseline ACQ-7 score = ACQ score recorded at V2 (Week 0) Day 1, before randomization; FEV1=Forced expiratory volume in the 1st second;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8

,,,,
Interventionscore on a scale (Least Squares Mean)
Week 4Week 8
Treatment A (CHF 718 pMDI 100 µg TDD)-0.43-0.53
Treatment B (CHF 718 pMDI 400 µg TDD)-0.53-0.58
Treatment C (CHF 718 pMDI 800 µg TDD)-0.49-0.66
Treatment D (Placebo)-0.27-0.43
Treatment E (QVAR^®, 320 µg TDD)-0.47-0.64

Average Use of Rescue Medication - Change From Baseline

"Change from baseline in average use of rescue medication, during Inter-visit period 1, Inter-visit period 2, Entire treatment period.~Definitions:~Baseline=For the efficacy variable -- average use of rescue medication -- derived from the electronic diary (eDiary), baseline values were the averages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Interventionpuffs/day (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)-0.11-0.12-0.11
Treatment B (CHF 718 pMDI 400 µg TDD)-0.27-0.35-0.31
Treatment C (CHF 718 pMDI 800 µg TDD)-0.14-0.25-0.20
Treatment D (Placebo)0.070.010.04
Treatment E (QVAR^®, 320 µg TDD)-0.13-0.18-0.15

Overall Daily Asthma Symptoms Scores - Change From Baseline

"Overall daily asthma symptoms scores - Change From Baseline (am and pm).~Subjects had to record asthma symptom score (overall symptoms, cough, wheeze, chest tightness and breathlessness) in the am (night-time asthma symptom score) and in the pm (daytime asthma symptom score). These data were collected in the subject's diary. Daily asthma symptoms score were performed separately for am score and pm score and also as a total, where the total equals the sum of the am and pm scores. Degree of asthma symptoms by score: 0=None, 1=Mild, 2=Moderate, and 3=Severe.~Baseline=Averages values during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Interventionscore on a scale (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)-0.1-0.1-0.1
Treatment B (CHF 718 pMDI 400 µg TDD)-0.1-0.1-0.1
Treatment C (CHF 718 pMDI 800 µg TDD)-0.1-0.1-0.1
Treatment D (Placebo)0.0-0.00.0
Treatment E (QVAR^®, 320 µg TDD)-0.1-0.1-0.1

Percentage (%) of Asthma Control Days - Change From Baseline

"Change from baseline in percentage (%) of asthma control days, during Inter-visit period 1, Inter-visit period 2, Entire treatment period.~This outcome measure was calculated according to the following definition: Days with a total daily morning + evening asthma score = 0 AND No rescue medication use.~Definitions:~Baseline=For the efficacy variable -- asthma control days -- derived from the eDiary, baseline values were the averages/percentages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Intervention% of asthma control days (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)7.314.310.8
Treatment B (CHF 718 pMDI 400 µg TDD)10.616.313.4
Treatment C (CHF 718 pMDI 800 µg TDD)10.417.513.9
Treatment D (Placebo)5.010.57.7
Treatment E (QVAR^®, 320 µg TDD)12.820.6316.7

Percentage (%) of Asthma Symptoms-free Days - Change From Baseline

"Change from baseline in Percentage (%) of asthma symptoms-free days.~Asthma symptoms-free days is the number of days with a total asthma score=0 (daily morning plus evening asthma score).~Subjects recorded asthma symptom score as described in the Outcome measure #7.~Definitions:~Baseline=For the efficacy variables -- daytime and night-time asthma symptom scores -- derived from the eDiary, baseline values were the averages/percentages recorded during the run-in period;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Intervention% of of asthma symptom-free days (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)8.616.412.5
Treatment B (CHF 718 pMDI 400 µg TDD)10.517.013.8
Treatment C (CHF 718 pMDI 800 µg TDD)10.117.213.6
Treatment D (Placebo)5.711.78.7
Treatment E (QVAR^®, 320 µg TDD)12.821.217.0

Percentage (%) of Rescue Medication-free Days - Change From Baseline

"Change from baseline in percentage (%) of rescue medication-free days. An increased value indicates improvement from baseline.~Definitions:~Baseline=For the efficacy variable -- percentage (%) of rescue medication-free days -- derived from the electronic diary (eDiary), baseline values were the averages/percentages recorded during the run-in period.~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
Intervention% of rescue medication-free days (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)5.98.97.4
Treatment B (CHF 718 pMDI 400 µg TDD)9.013.111.1
Treatment C (CHF 718 pMDI 800 µg TDD)6.110.08.1
Treatment D (Placebo)1.54.12.8
Treatment E (QVAR^®, 320 µg TDD)7.711.29.5

Pre-dose Morning FVC at Week 4 and 8 - Change From Baseline

"Change from baseline in pre-dose morning FVC at Week 4 and 8.~Spirometry, used to measure FVC, was performed according to internationally accepted standards.~Definitions:~Baseline=Baseline values for pre-dose FVC were the average of measurements taken at V2 (Week 0) at 45 minutes and 15 minutes pre-dose; FVC=Forced vital capacity;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8

,,,,
InterventionLitres (Least Squares Mean)
Week 4Week 8
Treatment A (CHF 718 pMDI 100 µg TDD)0.0360.014
Treatment B (CHF 718 pMDI 400 µg TDD)0.0990.089
Treatment C (CHF 718 pMDI 800 µg TDD)0.0660.036
Treatment D (Placebo)0.023-0.016
Treatment E (QVAR^®, 320 µg TDD)0.0560.063

Pre-dose Peak Expiratory Flow (PEF) (L/Min) (Morning and Evening) - Change From Baseline

"Change from baseline in pre-dose Peak Expiratory Flow (PEF) (Liters/min), morning and evening measurements.~Definitions:~Baseline=For the efficacy variable -- morning and evening PEF -- derived from the eDiary, the baseline values were the averages/percentages recorded during the run-in period; PEF=evening peak expiratory flow;~Inter-visit period 1=Starts from the pm assessment of the Start of the Randomized Treatment Period to the am assessment at Visit 3 (Week 4);~Inter-visit Period 2=Starts from the pm assessment of the day the subject returns to the clinic (Visit 3) to the am assessment of the date of Visit 4 (Week 8);~Entire treatment period=Average of 8 weeks;~am=morning pm=evening" (NCT03084718)
Timeframe: Baseline (average of the 2-week run-in period); Inter-visit period 1 (average of the first 4 weeks); Inter-visit period 2 (average of the last 4 weeks); Entire treatment period (average of 8 weeks)

,,,,
InterventionLiters/min (Least Squares Mean)
Inter-visit period 1Inter-visit period 2Entire treatment period
Treatment A (CHF 718 pMDI 100 µg TDD)-2-4-3
Treatment B (CHF 718 pMDI 400 µg TDD)-330.3
Treatment C (CHF 718 pMDI 800 µg TDD)-4-5-4
Treatment D (Placebo)-6-4-4.9
Treatment E (QVAR^®, 320 µg TDD)021

Vital Signs (Systolic and Diastolic Blood Pressure) - Change From Baseline

"Vital signs (systolic and diastolic blood pressure) at baseline, week 4, and week 8.~Change from baseline.~Definitions:~Baseline=Baseline values were defined at visit 2 (Week 0) pre-dose; DBP=Diastolic blood pressure; SBP=Systolic blood pressure;" (NCT03084718)
Timeframe: Baseline, Week 4, Week 8

,,,,
InterventionmmHg (Mean)
SBP, Week 4SBP, Week 8DBP, Week 4DBP, Week 8
Treatment A (CHF 718 pMDI 100 µg TDD)-0.41.0-0.10.8
Treatment B (CHF 718 pMDI 400 µg TDD)1.02.50.21.0
Treatment C (CHF 718 pMDI 800 µg TDD)0.50.8-0.80.3
Treatment D (Placebo)0.60.20.1-0.5
Treatment E (QVAR^®, 320 µg TDD)0.0-0.90.81.2

Reviews

1 review available for albuterol and Obesity

ArticleYear
Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2010, Volume: 47, Issue:1

    Topics: Acetates; Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Asthma; Body Mass Index; Cyclopro

2010

Trials

4 trials available for albuterol and Obesity

ArticleYear
Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults.
    The Journal of allergy and clinical immunology, 2015, Volume: 136, Issue:3

    Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Airway Obstruction; Albuterol; Anti-As

2015
The effect of caffeine and albuterol on body composition and metabolic rate.
    Obesity (Silver Spring, Md.), 2015, Volume: 23, Issue:9

    Topics: Adolescent; Adult; Albuterol; Animals; Body Composition; Caffeine; Cross-Over Studies; Double-Blind

2015
Impact of obesity on the severity and therapeutic responsiveness of acute episodes of asthma.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2011, Volume: 48, Issue:6

    Topics: Adult; Albuterol; Asthma; Body Mass Index; Body Weight; Emergency Service, Hospital; Hospitalization

2011
Catecholamine-stimulated potassium transport in erythrocytes from normal and obese subjects.
    Minerva medica, 1992, Volume: 83, Issue:10

    Topics: Adult; Albuterol; Erythrocytes; Female; Humans; Male; Middle Aged; Obesity; Potassium; Respiratory H

1992

Other Studies

21 other studies available for albuterol and Obesity

ArticleYear
Mechanical effects of obesity on central and peripheral airway resistance in nonasthmatic early pubescent children.
    Pediatric pulmonology, 2022, Volume: 57, Issue:12

    Topics: Airway Resistance; Albuterol; Bronchodilator Agents; Child; Humans; Lung; Obesity

2022
Bronchodilator response does not associate with asthma control or symptom burden among patients with poorly controlled asthma.
    Respiratory medicine, 2023, Volume: 218

    Topics: Albuterol; Asthma; Bronchodilator Agents; Female; Forced Expiratory Volume; Humans; Male; Obesity; P

2023
Association of obesity with severity outcomes in hospitalized pediatric asthma exacerbations.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 2022, Volume: 59, Issue:1

    Topics: Adolescent; Albuterol; Asthma; Child; Child, Preschool; Hospitalization; Humans; Intensive Care Unit

2022
Obesity alters the uterine environment before pregnancy.
    The Journal of nutritional biochemistry, 2018, Volume: 62

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Cell Proliferation; Diet; Down-Regulation;

2018
Peripheral airways dysfunction in obesity reflects increased bronchomotor tone.
    The Journal of allergy and clinical immunology, 2015, Volume: 135, Issue:3

    Topics: Adult; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Female; Humans; Male; Obesity; R

2015
Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma.
    Chest, 2015, Volume: 147, Issue:6

    Topics: Administration, Inhalation; Adolescent; Adrenal Cortex Hormones; Albuterol; Asthma; Black People; Br

2015
Postnatal overnutrition in mice leads to impaired pulmonary mechanics in response to salbutamol.
    The journal of physiological sciences : JPS, 2016, Volume: 66, Issue:3

    Topics: Albuterol; Animals; Animals, Newborn; Bronchodilator Agents; Female; Lung; Male; Mice; Obesity; Over

2016
Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects.
    Atherosclerosis, 2009, Volume: 204, Issue:2

    Topics: Adenosine Diphosphate; Adult; Albuterol; Arginine; Body Composition; C-Reactive Protein; Cohort Stud

2009
Influence of obesity on control in asthmatic Japanese patients defined by the Japanese definition of obesity.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:18

    Topics: Adrenal Cortex Hormones; Adult; Aged; Albuterol; Anti-Asthmatic Agents; Asthma; Female; Humans; Inci

2011
Lipolytic and nutritive blood flow response to beta-adrenoceptor stimulation in situ in subcutaneous abdominal adipose tissue in obese men.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003, Volume: 27, Issue:2

    Topics: Abdominal Wall; Adipocytes; Adipose Tissue; Adrenergic beta-Agonists; Albuterol; Dobutamine; Dose-Re

2003
Impaired beta-adrenergically mediated lipolysis in skeletal muscle of obese subjects.
    Diabetologia, 2004, Volume: 47, Issue:8

    Topics: Adrenergic beta-Agonists; Albuterol; Body Composition; Dose-Response Relationship, Drug; Humans; Lip

2004
Vascular endothelial dysfunction tested by blunted response to endothelium-dependent vasodilation by salbutamol and its related factors in uncomplicated pre-menopausal obese women.
    International journal of obesity (2005), 2005, Volume: 29, Issue:2

    Topics: Abdomen; Adipose Tissue; Adult; Albuterol; Anthropometry; Endothelium, Vascular; Female; Humans; Mid

2005
beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure.
    The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:4

    Topics: Adult; Albuterol; Blood Pressure; Codon; Energy Metabolism; Fatty Acids, Nonesterified; Female; Glyc

2005
Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma.
    Respiratory medicine, 2007, Volume: 101, Issue:11

    Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Ant

2007
Body mass index and response to emergency department treatment in adults with severe asthma exacerbations: a prospective cohort study.
    Chest, 2007, Volume: 132, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Albuterol; Analysis of Variance; Anti-Asthmatic Agents; Asthma; Bo

2007
Beta 3-adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity.
    Journal of cellular biochemistry, 1995, Volume: 58, Issue:4

    Topics: Adenylate Cyclase Toxin; Adenylyl Cyclases; Adipocytes; Adipose Tissue; Adrenergic beta-Agonists; Al

1995
[Obesity: a multifactorial disorder with difficult long-term treatment].
    La Clinica terapeutica, 1994, Volume: 145, Issue:11

    Topics: Adolescent; Adult; Albuterol; Appetite Depressants; Biguanides; Cimetidine; Diet, Reducing; Female;

1994
Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants.
    Pharmacology, biochemistry, and behavior, 1993, Volume: 46, Issue:3

    Topics: Albuterol; Animals; Appetite Depressants; Cyclohexanes; Dextroamphetamine; Drug Tolerance; Eating; E

1993
beta(1)- and beta(2)-Adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men.
    The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:5

    Topics: Adult; Albuterol; Dobutamine; Energy Metabolism; Fatty Acids, Nonesterified; Hemodynamics; Humans; L

2001
[Glycoregulation during IV infusion of salbutamol in normal and obese women (proceedings)].
    Diabete & metabolisme, 1976, Volume: 2, Issue:3

    Topics: Albuterol; Blood Glucose; Female; Humans; Infusions, Parenteral; Obesity

1976
Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists.
    Brain research, 1992, Aug-07, Volume: 587, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Animals; Clonidine; Dose-Response Relationship, Drug; Drug Inte

1992